A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA and is currently in development for the treatment of hospital acquired Gramnegative infections.
Epistemonikos ID: 85c63ec0314eeedd0446e60bd1848b076ced6ec7
First added on: May 11, 2024